REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “ ...

Core Insights - Pulmonx Corporation reported a total worldwide revenue of $21.5 million for Q3 2025, reflecting a 5% increase from $20.4 million in Q3 2024, and a 4% increase on a constant currency basis [4][9] - The company aims to leverage its operational foundation to expand Zephyr Valve treatment volumes while maintaining a commitment to sustainable, profitable growth [3][4] Financial Performance - U.S. revenue for Q3 2025 was $14.0 million, a 1% increase year-over-year, while international revenue reached $7.5 million, marking a 15% increase compared to Q3 2024 [4][9] - Gross profit for Q3 2025 was $16.1 million, with a gross margin of 75%, up from 74% in the same period last year [5][9] - Operating expenses increased by 4% to $30.4 million, driven by higher clinical, development, and commercial investments [5][9] - The net loss for Q3 2025 was $14.0 million, or $0.34 per share, slightly improved from a net loss of $14.1 million, or $0.36 per share, in Q3 2024 [6][9] 2025 Financial Outlook - Pulmonx updated its 2025 financial outlook, expecting total revenue to be in the range of $89 million to $90 million, with a gross margin of approximately 73% [7][9] - Total operating expenses for the full year 2025 are projected to be between $125 million and $126 million, including about $21 million in non-cash stock-based compensation [7][9] Leadership Changes - Glen French was reappointed as President and CEO, and Derrick Sung was appointed as COO and CFO [9]

Group 1: Penny Stocks Overview - Five penny stocks to watch include Beyond Meat, Strive, VSee Health, Pulmonx, and Datavault AI, identified by MarketBeat's stock screener tool [2] - Penny stocks are defined as shares of very small or microcap companies trading at low per-share prices, traditionally under $1 but commonly under $5 in the U.S. [2] - These stocks often trade on over-the-counter markets, characterized by low liquidity, wide bid-ask spreads, high volatility, and a greater risk of price manipulation and loss [2] Group 2: Company Profiles - Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products across various platforms including beef, pork, and poultry, with distribution through grocery and foodservice channels [3] - Strive (Asset Entities Inc.) provides social media marketing and content delivery services, focusing on platforms like Discord and TikTok, and offers investment education and marketing services [4] - Pulmonx Corporation specializes in minimally invasive devices for chronic obstructive pulmonary diseases, offering products like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System [5] - Datavault AI Inc. operates data management and supercomputer platforms, providing data technology and software solutions, previously known as WiSA Technologies, Inc. [6]

Leadership Changes - Glen French has been reappointed as President and Chief Executive Officer of Pulmonx Corporation, effective immediately [1][3] - Derrick Sung has been appointed as Chief Operating Officer and Chief Financial Officer, effective November 3, 2025 [1][3] - Steve Williamson and Mehul Joshi have resigned from their roles but will serve in advisory capacities until December 1, 2025 [1][3] Financial Performance - Preliminary revenue for the third quarter of 2025 is anticipated to be approximately $21.5 million [4] - The company plans to provide further details on its third quarter results during a conference call rescheduled for November 12, 2025 [4][6] Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [9] - The company's Zephyr Endobronchial Valve is a standard treatment option for patients with severe emphysema and is commercially available in over 25 countries [9]

Core Insights - Pulmonx Corporation will release its financial results for Q3 2025 on October 29, 2025, after market close, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET [1] Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3] - The company's key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, aimed at treating patients with severe emphysema/COPD [3] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is available in over 25 countries, recognized in global treatment guidelines as a standard care option for improving patient outcomes [3]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company's key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX™ Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries, recognized as a standard treatment option for improving patient outcomes [2] Upcoming Investor Conferences - Pulmonx management will present at the Wells Fargo Healthcare Conference on September 4 at 1:30 pm PT/4:30 pm ET in Boston, MA, featuring a fireside chat and 1x1 meetings [1] - The company will also participate in the Lake Street Best Ideas Growth (BIG9) Conference on September 11 in New York, NY, focusing on 1x1 meetings [1] - A live and archived webcast of the fireside chat will be accessible on the "Investors" section of the Pulmonx website [1]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval and is recognized as a "breakthrough device," being commercially available in over 25 countries and included in global treatment guidelines [2] Upcoming Events - Pulmonx will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025, at 7:00 AM PT / 10:00 AM ET [1] - A live and archived webcast of the presentation will be accessible on the "Investors" section of the Pulmonx website [1]

Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [2] - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTrax™ Platform, and StratX Lung Analysis Reports, which are designed for patients with severe emphysema/COPD [2] - The Zephyr Valve has received FDA pre-market approval and is recognized as a "breakthrough device," being commercially available in over 25 countries and included in global treatment guidelines [2] Upcoming Events - Pulmonx will present at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on June 11, 2025, at 7:00 AM PT / 10:00 AM ET [1] - A live and archived webcast of the presentation will be accessible on the "Investors" section of the Pulmonx website [1]

Core Insights - Pulmonx Corporation reported a strong start to 2025, emphasizing its strategy to expand patient access to Zephyr Valves and highlighting solid commercial performance [3][4]. Financial Performance - Total worldwide revenue for Q1 2025 was $22.5 million, a 20% increase from $18.9 million in Q1 2024, and a 21% increase on a constant currency basis [4][9]. - U.S. revenue reached $14.2 million, reflecting an 11% year-over-year increase, while international revenue was $8.3 million, marking a 39% increase compared to Q1 2024, and a 43% increase on a constant currency basis [4][9]. - Gross profit for Q1 2025 was $16.3 million, with a gross margin of 73%, down from 75% in the same period of 2024 [5][9]. - Operating expenses increased to $30.9 million, up 8% from $28.6 million in Q1 2024, primarily due to higher commercial investments [5][9]. - The net loss for Q1 2025 was $14.4 million, or $0.36 per share, compared to a net loss of $13.7 million, also $0.36 per share, in Q1 2024 [6][9]. 2025 Financial Outlook - The company reaffirmed its full-year 2025 revenue guidance, expecting it to be in the range of $96 million to $98 million, with a gross margin of approximately 74% [7][8]. - Total operating expenses for 2025 are anticipated to be between $133 million and $135 million, including about $22 million in non-cash stock-based compensation [7][8]. Recent Developments - Pulmonx amended its loan agreement with CIBC Innovation Banking to extend the interest-only period through October 2027 [9]. - The U.S. Department of Justice declined to intervene in a case against Pulmonx, concluding the civil investigative demand [9].

Core Viewpoint - Pulmonx Corporation is set to release its financial results for Q1 2025 on April 30, 2025, and will host a conference call to discuss these results [1]. Company Overview - Pulmonx Corporation is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD) [3]. - The company’s key products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report, which are designed for patients with severe emphysema/COPD [3]. - The Zephyr Valve has received FDA pre-market approval as a "breakthrough device" and is commercially available in over 25 countries, recognized as a standard treatment option for improving the quality of life in patients with severe emphysema [3].